(Q40667069)

22 September 2017

Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient (English)

1 reference

22 September 2017

R Ramphal

1

1 reference

22 September 2017

R Gucalp

2

1 reference

22 September 2017

C Rotstein

3

1 reference

22 September 2017

M Cimino

4

1 reference

22 September 2017

D Oblon

5

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 June 1996

1 reference

American Journal of Medicine

22 September 2017

1 reference

22 September 2017

100

1 reference

22 September 2017

83S-89S

1 reference

22 September 2017

6A

1 reference

From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

More extended-spectrum beta-lactamases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

In vitro studies of BMY-28142, a new broad-spectrum cephalosporin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

Susceptibility of new beta-lactams to the expanded-spectrum beta-lactamase CTX-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900113-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(96)00113-1

1 reference

22 September 2017

1 reference